Department of Neurosurgery, Gamma Knife Center, Komaki City Hospital, Komaki, Japan.
Department of Neurosurgery, Gamma Knife Center, Komaki City Hospital, Komaki, Japan.
Int J Radiat Oncol Biol Phys. 2020 Nov 1;108(3):725-733. doi: 10.1016/j.ijrobp.2020.05.029. Epub 2020 May 29.
Vestibular schwannomas (VSs) are benign; thus, understanding long-term tumor control and late adverse radiation effects of stereotactic radiosurgery (SRS) through current radiosurgical techniques is important to inform treatment decisions. Our aim was to clarify long-term tumor control rates and incidence of late adverse radiation effects in patients with VSs followed for 5 years or longer after SRS.
Altogether, 615 patients with VSs (excluding neurofibromatosis type 2 and partially treated tumors) followed for 5 years or longer after SRS using recent radiosurgical techniques were evaluated. All patients were treated at a margin dose of less than 14 Gy. All tumors were classified into 4 categories: type A (intracanalicular tumor, 87 patients [14%]), type B (cerebellopontine angle [CPA] tumor, 325 patients [53%]), type C (CPA tumor compressing the brain stem, 138 patients [22%]), and type D (CPA tumor compressing the brain stem with a deviation of the fourth ventricle, 65 patients [11%]). Median tumor volume was 2.0 cm and median marginal dose was 12 Gy.
Median follow-up period was 158 months. Actuarial 5-, 10-, and 15-year or longer local control (LC) rates were 93%, 91%, and 89%, respectively. Tumor type (P < .001, hazard ratio 2.389) and number of prior surgeries (P = .007, hazard ratio 1.698) were significant for LC. Depending on the tumor type, the actuarial 10-year LC rates were 100%, 93%, 88%, and 70% in type A, B, C, and D tumors, respectively. No patient developed persistent facial palsy. Twenty patients (3.3%) developed delayed cysts. One patient developed malignant transformation (0.2%).
SRS is a safe and effective treatment for VSs in the long term, excluding VSs compressing the brain stem with a deviation of the fourth ventricle. Delayed cysts such as cyst formation, enlarged preexisting cysts or extratumoral cysts, and malignant transformation should be considered possible causes of long-term treatment failures.
前庭神经鞘瘤(VSs)是良性的;因此,了解当前立体定向放射外科(SRS)技术治疗后 VSs 的长期肿瘤控制和晚期放射性不良反应对于治疗决策至关重要。我们的目的是阐明接受 SRS 治疗后随访 5 年或更长时间的 VSs 患者的长期肿瘤控制率和晚期放射性不良反应发生率。
共评估了 615 例接受 SRS 治疗后随访 5 年或更长时间的 VSs 患者(不包括神经纤维瘤病 2 型和部分治疗的肿瘤)。所有患者均采用低于 14 Gy 的边缘剂量治疗。所有肿瘤均分为 4 类:A型(管内肿瘤,87 例[14%])、B 型(桥小脑角[CPA]肿瘤,325 例[53%])、C 型(CPA 肿瘤压迫脑干,138 例[22%])和 D 型(CPA 肿瘤压迫脑干伴第四脑室偏斜,65 例[11%])。中位肿瘤体积为 2.0 cm,中位边缘剂量为 12 Gy。
中位随访时间为 158 个月。5、10 和 15 年及以上的局部控制(LC)率分别为 93%、91%和 89%。肿瘤类型(P<0.001,风险比 2.389)和既往手术次数(P=0.007,风险比 1.698)对 LC 有显著影响。根据肿瘤类型,A型、B 型、C 型和 D 型肿瘤的 10 年 LC 率分别为 100%、93%、88%和 70%。无患者发生持续性面瘫。20 例(3.3%)发生迟发性囊肿。1 例发生恶性转化(0.2%)。
SRS 是一种安全有效的 VSs 长期治疗方法,不包括压迫第四脑室偏斜的脑干 VSs。应考虑迟发性囊肿(如囊肿形成、增大的原有囊肿或肿瘤外囊肿)和恶性转化作为长期治疗失败的可能原因。